strattera online



Atomoxetine (Strattera)

atomoxetine hydrochloride



Atomoxetine (Strattera) is a medication indicated for the treatment of attention deficit hyperactivity disorder (ADHD), especially in children. It is sold as atomoxetine hydrochloride (atomoxetine HCl), i.e. in the form of the hydrochloride salt of atomoxetine. The medication has been manufactured and distributed as Strattera by the American-British company Eli Lilly since December 2002. Besides Strattera atomoxetine, nowadays there may be found other brand names of the medication produced by different manufacturers around the world (they include Tomoxetine and Attentin), though in the United States there are still no generics for Strattera available due to the agreement with Eli Lilly & Co. and legal restrictions on the manufacturing of patented drugs. The patent for Strattera expires in 2017, and buying any medication called "generic Strattera", or "generic atomoxetine" now can be risky due to the fact that all those medications are almost surely fake, or substandard and potentially dangerous. Unless the patent situation changes in some way we shall not be able to buy generic atomoxetine (Strattera) in the United States until 2017. However, there is one more thing. Tomoxetine and Attenin are... sometimes classified as generics for Strattera. Perhaps, when buying "generic Strattera", you may buy these medications.


(3R)-N-methyl-3-(2-methylphenoxy)-3-phenyl-propan-1-amine; (R)-N-methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine


Atomoxetine (Strattera) belongs to the so-called SNRIs - serotonin-norepinephrine reuptake inhibitors. The medication increases levels of serotonin and norepinephrine by inhibiting their reabsorption into cells in the brain, thus affecting our mood and mind condition. It is classified as a non-stimulant drug, and it is the first and for the time being the only non-stimulant approved for the treatment of ADHD. Atomoxetine (Strattera) is considered to have less abuse potential than stimulants used for the treatment of ADHD, and is not scheduled as a controlled substance, though FDA insisted on warning that taking atomoxetine (Strattera) increases the risk of suicidal thoughts among children and teenagers. The warning was added to Strattera's label on September 30th, 2005, which immediately cut down atomoxetine Stattera sales greatly in the US.


Atomoxetine (Strattera) is approved for the treatment of ADHD. Though the symptoms of attention deficit and / or hyperactivity disorder is usually observed among children (fidgetting, uncontrolled running around, shouting, unableness to listen carefully, etc), adults can suffer from some forms of ADHD, too. So, the medication may be prescribed for both children and adults, though the problem of lack of concentration in adults looks different from the problem in children and teenagers. However, before starting treatment with Strattera (atomoxetine) one has to make sure that symptoms of the disorder are really severe, and has been observed in the patient in different circumstances for at least six months.

Atomoxetine (Strattera) should be used in complex with general social, educational and mental therapy. The condition of the patient treated with atomoxetine should be constantly monitored by his family and the doctor. Also, the prescribed dosage of Strattera should not be exceeded.

Atomoxetine (Strattera) is normally prescribed for a prolonged period. During the first weeks of treatment patients may experience weariness or dormancy. The expected beneficial effects of the medication are usually observed after three to four weeks of usage, when the body and brain adapt to atomoxetine (Strattera).